Novo Bets on a Next Chapter as Lilly Widens Its GLP-1 Lead
Novo Nordisk is selling investors on a turnaround while Eli Lilly keeps taking ground in obesity drugs. The latest closing prices show which story the market believes.
Novo Nordisk is pitching investors on a turnaround it calls its "next chapter" while analysts say Eli Lilly holds advantages that could keep it atop the obesity drug market, with LLY closing at 1181.89 (+2.68%) and NVO at 38.62 (+1.18%) on Sept. 24, 2026.
Novo Nordisk is asking investors to look past a bruising stretch and buy into what the company frames as its "next chapter." The problem is that the chapter being written elsewhere — at Eli Lilly — is the one the market keeps rewarding.
Novo (ticker NVO) closed its most recent session at 38.62, up 1.18% from a prior close of 38.17, with the day's range running from 37.92 to 38.72. Lilly (ticker LLY) closed at 1181.89, up 2.68% from 1150.99, having traded between 1151.00 and 1197.79. Those are last-traded prices as of 20:00 GMT on Sept. 24, 2026; markets were closed at the time of writing. On the day, Lilly added roughly 30.90 points while Novo added 0.45 — a gap that captures, in miniature, how differently the two GLP-1 franchises are being valued.
The backdrop, as CNBC reported, is that Novo is working to turn itself around while some analysts argue Lilly holds structural advantages that could help it maintain its position at the top of the obesity drug market.
What "turning itself around" actually has to fix
Turnaround is a heavy word for a company that, only a few years ago, was the defining growth story in European pharmaceuticals. GLP-1 medicines — drugs that mimic a gut hormone called glucagon-like peptide-1 to blunt appetite and slow digestion — took Novo from a diabetes specialist to one of the most watched stocks on the continent. The category did not shrink. Novo's share of the narrative did.
A credible next chapter has to answer three questions at once. Can Novo defend the patients it already has as prescribers get more choice? Can it deliver a pipeline asset that reframes the conversation rather than matching a rival's profile? And can it convince investors that the commercial machinery — manufacturing, payer negotiation, direct-to-patient channels — is as good as the science?
None of those is solved by a single announcement. That is why the phrase "next chapter" is doing so much work: it asks the market for time, and time is precisely what a competitor with momentum is trying to deny.
Why analysts keep pointing at Lilly's position
The argument that Lilly can hold the top spot is not primarily about any one molecule. It is about accumulation. A company that is gaining ground in a category tends to gain it on several fronts simultaneously — prescription volume, breadth of approved uses, manufacturing capacity, and the ability to price and contract aggressively because scale absorbs the hit.
Once that flywheel is turning, the incumbent's advantage compounds in ways that are hard to reverse. Physicians build habits. Health plans write formularies that are sticky for a year at a time. Employers negotiate coverage around the product their members already use. A challenger does not just need a better drug; it needs a reason for all of those parties to do the paperwork of switching.
That is the shape of the analyst case the lead describes, and it is consistent with what the tape showed on Sept. 24: Lilly outpacing Novo on a day when the broad market went nowhere. The S&P 500 proxy SPY closed at $767.18, down 0.08%. The Nasdaq 100 proxy QQQ closed at $741.10, essentially flat at -0.01%. The Dow proxy DIA closed at $512.68, off 0.32%. Neither drug stock's move was an index story. Both were company stories, and they pointed in the same direction with different force.
How to read two prices that are not comparable
Both were company stories, and they pointed in the same direction with different force.
A word of caution on the headline numbers. Lilly's last close of 1181.89 is about 30.6 times Novo's 38.62, but that tells you nothing about relative size or value. Share prices reflect how many shares a company has issued and, in cross-border comparisons, which listing and currency you are looking at. A Danish company's depositary receipt and a U.S.-listed large cap are quoted on entirely different bases.
What the daily percentage move does tell you is direction of conviction. Lilly's 2.68% advance was more than twice Novo's 1.18% in percentage terms — and Lilly closed nearer the low end of its intraday high at 1197.79 than the top, while Novo finished close to its session peak of 38.72. Single sessions are noise. Sequences of sessions that lean the same way are not, and that is the pattern investors in this pair have been tracking.
What would change the story
For Novo, the catalysts that matter are the ones that cannot be matched quickly: data in an indication the category has not yet claimed, a formulation or delivery advantage that shows up in real prescribing behavior, or evidence that supply constraints have stopped costing it patients. Management commentary about a next chapter is a promise; a readout is a fact. The market has shown it will pay for the second and discount the first.
For Lilly, the risk is the mirror image. Leadership in a category this profitable invites everything from pricing pressure by payers and governments to scrutiny of long-term safety and adherence data — patients who stop taking a drug are patients a rival can recruit. Compounding, reimbursement policy and the arrival of oral formulations all sit in the path of any incumbent trying to defend a franchise.
There is also a version of this where both companies do well. Obesity is not a niche, and a market that keeps expanding can support two dominant sellers with very different share positions. The competitive question is about rank and margin, not about survival.
What to watch next
- Whether Novo attaches specific timelines and assets to the "next chapter" framing, or leaves it as strategy language.
- Prescription-trend data, which is the cleanest read on whether Lilly's gains are still accelerating or plateauing.
- Payer and formulary decisions heading into the next coverage year, where switching costs are set for months at a time.
- Whether the pair keeps trading as a relative-value trade — Lilly up on days Novo drifts — or whether the correlation reasserts itself on category-wide news.
Novo's pitch is that the last chapter was not the whole book. That is a reasonable thing for management to say and a hard thing for investors to price. Until the evidence lands, the prices on the screen are the market's provisional verdict, and on Sept. 24 that verdict went Lilly's way again.
Key facts
- NVO last close: 38.62, +1.18% (as of 20:00 GMT, Sept. 24, 2026)
- LLY last close: 1181.89, +2.68% (as of 20:00 GMT, Sept. 24, 2026)
- Benchmark backdrop: SPY $767.18 (-0.08%), QQQ $741.10 (-0.01%), DIA $512.68 (-0.32%)
- Core issue: Novo pitches a turnaround while analysts cite Lilly advantages in obesity drugs
Frequently asked questions
What did Novo Nordisk and Eli Lilly shares do most recently?
As of the last trade at 20:00 GMT on Sept. 24, 2026, Novo Nordisk (NVO) closed at 38.62, up 1.18% from a prior close of 38.17, with an intraday range of 37.92 to 38.72. Eli Lilly (LLY) closed at 1181.89, up 2.68% from 1150.99, trading between 1151.00 and 1197.79 during the session.
What is a GLP-1 drug?
GLP-1 stands for glucagon-like peptide-1, a hormone released in the gut that helps regulate blood sugar and appetite. Drugs that mimic it slow stomach emptying and reduce hunger signals, which is why medicines developed for type 2 diabetes became central to obesity treatment. Novo Nordisk and Eli Lilly are the two dominant developers in the category.
Why do analysts think Eli Lilly can stay on top?
According to the reporting, some analysts say Lilly holds advantages that could help it maintain its leading position in the obesity drug market. In practice, leadership in this category compounds through prescriber habit, formulary placement, manufacturing scale and contracting power, all of which make switching costly for payers and physicians even when a rival product is competitive.
Does Lilly's higher share price mean it is the better investment?
No. Share price alone says nothing about value or company size, because it depends on how many shares are outstanding and, for cross-border comparisons, on which listing and currency is being quoted. Lilly's last close is roughly 30.6 times Novo's, but that ratio is an artifact of share structure, not a measure of relative worth.
What does Novo mean by its 'next chapter'?
It is the framing Novo Nordisk is using as it works to turn itself around after losing ground in GLP-1s. The phrase signals a forward-looking strategy rather than a specific disclosed asset or timeline. Investors will generally discount strategy language until it is matched by concrete clinical data, prescription trends or commercial results.
Was the move in these two stocks driven by the broader market?
No. The main U.S. benchmarks were close to flat on Sept. 24, 2026: the S&P 500 proxy SPY closed at $767.18, down 0.08%; the Nasdaq 100 proxy QQQ at $741.10, down 0.01%; and the Dow proxy DIA at $512.68, down 0.32%. Both drugmakers rose against that neutral backdrop, making the moves company-specific.
